Skip to content

Evaluation of laser lancing devices in patients with diabetes mellitus and high bleeding risk

Evaluation of laser lancing devices in patients with diabetes mellitus accompanying diseases or taking medications leading high bleeding risk

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0007706
Enrollment
100
Registered
2022-09-16
Start date
2022-09-01
Completion date
Unknown
Last updated
2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Koera University Guro Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - subjects whose platelet level above 50,000/uL and below 120,000/uL or who use dual anti-platelet agents - adults who can lance same finger in each hand - subjects who understand risk of participating in the clinical research, who are able to communicate each other, who are able to follow rules of research - subjects who decide to participate in the clinical research volutarily and sign in the consent format after being informed purposes, methods, and expectation of the research

Exclusion criteria

Exclusion criteria: - subjects whose age is younger than 19 or older than 80 - students of research institutes - pregnant and lactating women - subjects who are note able to make decision - subjects who are in emergency or being hospitalized - subjects who cannot lance same finger from both hands - subjects who are infected by HIV in hospital records - subjects who are incompatible for research as researcher evaluated

Design outcomes

Primary

MeasureTime frame
bleeding time

Secondary

MeasureTime frame
glucose level;satisfaction score;pain score

Countries

Korea, Republic of

Contacts

Public ContactMin Jeong Park

Koera University Guro Hospital

minjeong87@gmail.com+82-2-2626-3046

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026